Background
==========

Primary salivary gland cancers (SGC) are a rare and highly diverse group of tumours regarding histology, clinical behaviour and responsiveness to therapy. The incidence of SGC is estimated to be 1.31/100,000/year, representing less than 5% of all head and neck malignancies, with equal sex distribution and average age of 47 years \[[@ref1], [@ref2]\].

The 2017 World Health Organization classification comprises more than 20 different malignant histologies for SGC, with specific features and outcomes. The impact of genetic alterations is increasing, despite restricted to diagnostic purposes so far \[[@ref2]\]. Mucoepidermoid carcinoma is the most frequent primary salivary malignancy, followed by adenoid cystic and acinic cell carcinoma \[[@ref3]\]. Parotid gland is the most frequent site of origin, accounting for 70% of cases, with only 10% to 15% arising in minor salivary glands. Nevertheless, malignancy rate has been described as only 25% for parotid neoplasms, compared to 82% for minor salivary glands and 43% for submandibular glands \[[@ref4]\].

It is recognised that risk factors for SGC include viruses, radiation exposure and occupation. Prognostic factors include stage---tumour size or extent (T), nodal status and extranodal extension (N) and presence of distant metastases (M) ---, location, histological type and grade \[[@ref5], [@ref6]\]. Also, perineural and lymphovascular invasion, and even male sex have been associated with poorer outcomes \[[@ref7], [@ref8]\].

Currently, upfront surgical resection remains the standard of care for locoregional disease, with elective neck dissection according to histology and clinical stage \[[@ref9], [@ref10]\]. Adjuvant radiotherapy can be performed in high grade, advanced stage disease or incomplete resection \[[@ref11]\], apparently with no benefit from concurrent chemotherapy \[[@ref12]\]. Chemotherapy is an option in metastatic or recurrent setting, with CAP regimen (cyclophosphamide, adriamycin and cisplatin) having the greatest amount of data, despite no clear benefit on survival or over single-agent therapy \[[@ref13], [@ref14]\]. Hormonal therapy has shown activity in androgen-receptor positive SGC, which is detected in various histologies and in the majority of cases of salivary duct carcinoma (SDC) \[[@ref15]\]. Also, there has been an increasing interest in defining routes to targeted therapies, with some preliminary evidence \[[@ref16], [@ref17]\].

In this study, we aim to review the incidence, pathology, clinical behaviour and outcomes in a cohort of patients with major SGC treated at a tertiary cancer centre over a 10-year period from 2006 to 2016.

Methods
=======

A retrospective cohort of patients with histological diagnosis of primary major SGC, admitted to a single tertiary cancer centre from March 2006 to July 2016, was evaluated.

Demographic and clinical-pathological features analysis was performed using descriptive statistics. Data were retrieved from patients' charts regarding demographics, presentation, pathology, treatment and outcomes, including disease-free survival (DFS) and overall survival (OS). DFS and OS were estimated by the Kaplan--Meier method and compared by Cox regression. DFS was defined as time between curative treatment and local or distant recurrence; OS was defined as time between diagnosis and death from any cause. Follow-up was updated as of 31th October, 2019.

Statistical analysis was performed using SPSS Statistics for MacOS, version 25.0 (SPSS, Chicago, IL). Statistical significance was set at *p* \< 0.05.

The study was conducted in accordance with the Declaration of Helsinki on biomedical research involving human subjects, and after the written approval of institutional ethics committee.

Results
=======

Between March 2006 and July 2016, 933 patients were diagnosed with salivary gland lesions in our institution, whose 32.9% (*n* = 307) had malignant histologies, and 10.0% (*n* = 93) were primary tumours. Median follow-up was 8 years (CI 95% 6.2--9.6). Demographics, clinical-pathological and treatment features are summarised in [Table 1](#table1){ref-type="table"}. Most patients were male and median age at diagnosis was 64 years (IQR, 23). The location of the primary tumour was mostly in parotid gland (76.3%, *n* = 71), followed by submandibular gland (22.6%, *n* = 21). The most frequent histological type was SDC (21.5%, *n* = 20), followed by adenoid cystic carcinoma (16.1%, *n* = 15) and mucoepidermoid carcinoma (14.0%, *n* = 13). Six cases of SDC (30%) arose in pleomorphic adenoma. All patients were submitted to surgery and most of them underwent adjuvant radiotherapy (74.2%, *n* = 69), in three cases with concurrent chemotherapy with cisplatin. A large number of patients were diagnosed with pT3 or pT4 disease (36.6%, *n* = 34) and with positive lymph nodes (18.3%, *n* = 17) although an important number of patients (31.2%, *n* = 29) had no lymph nodes removed (stage pNx). Eight patients were initially diagnosed with distant metastasis. Histological grade was classified as high in 24.7% (*n* = 23) of patients. Lymphovascular invasion was seen in 22.6% of patients (*n* = 21), perineural invasion in 37.6% (*n* = 35), carcinoma ex pleomorphic adenoma in 6.5% (*n* = 6) and extracapsular spread in 9.7% (*n* = 9). Facial nerve sacrifice during surgery was used as a surrogate for preoperative facial nerve involvement, and was present in 23.9% (*n* = 17) of patients who underwent parotidectomy. *ERBB2* and androgen receptor positivity was seen in two and six patients, from six and 11 analysed, respectively.

Distant metastasis at diagnosis were mainly seen in lung (four patients), but also in brain, bone, liver and skin, in one patient each. During follow-up, 34.1% (*n* = 29) of patients recurred, mainly locally (37.9%, *n* = 11), but also in lung (17.2%, *n* = 5), bone (10.3%, *n* = 3), liver (10.3%, *n* = 3), brain (3.4%, *n* = 1) and multiple sites (20.7%, *n* = 6). In the metastatic setting, nine patients were treated with systemic therapy, and chemotherapy regimens used were CAP and carboplatin with paclitaxel; one patient was treated with methotrexate in third line; and the patient with small cell carcinoma was treated with carboplatin and etoposide.

At 8 years, DFS was 54.6% and OS was 48.4% ([Figure 1](#figure1){ref-type="fig"}). The results of univariate Kaplan--Meier survival analyses are summarised in [Table 2](#table2){ref-type="table"}, and multivariable survival models in [Table 3](#table3){ref-type="table"}. In the univariate analysis, male sex, SDC, stage pT3-4, stage pN2-3, high histologic grade, lymphovascular invasion and perineural invasion were significant negative prognostic indicators for DFS and OS. Extracapsular spread was a significant negative prognostic indicator for OS, but not for DFS. In the multivariable analysis just histological type---SDC---kept significant negative impact in DFS, but not in OS; and high histologic grade in OS, but not in DFS.

Discussion
==========

Primary SGC are rare and heterogeneous, and there is also some geographic variation in the frequency of tumour types, resulting in poorly documented epidemiology \[[@ref2]\]. The incidence of major SGC is increasing, mainly parotid and smaller tumours, with regional and distant metastasis, probably due to earlier diagnosis and improved clinical staging. Aetiology and risk factors are not well established, thus the reason for this rising incidence is not well known \[[@ref18]\]. Since Portugal is a small country accounting, approximately, 10 million inhabitants, and our institution is the biggest in the country dedicated to the treatment of cancer, we present, probably, the largest national series of major SGC patients.

In our cohort, the most frequent histological type was SDC, which is estimated to represent only 9% of salivary tumours \[[@ref2]\], probably because our institution is a high-specialised oncology centre. Kleinsasser *et al* \[[@ref19]\] described SDC in 1968, as an aggressive adenocarcinoma which resembles high-grade breast ductal carcinoma. This entity has been increasingly diagnosed, and there is currently a growing interest from the scientific community, with multiple publications of institutional series \[[@ref20]--[@ref30]\]. Actually, SDC is characterised by a very aggressive behaviour, with high rates of local or distant recurrence and tumour-related death \[[@ref31], [@ref32]\]. This is mostly diagnosed in elderly men, predominantly in the parotid gland. Pain, facial palsy and presence of calcifications on computed tomography scans are suggestive features of SDC. Node metastasis, lymphovascular and perineural invasion, and positive surgical margins have been described as adverse prognostic factors \[[@ref31], [@ref32]\]. SDC frequently overexpresses *EGFR* and *ERBB2*, but it is not clear whether that expression is associated with poor prognosis, or the role of targeted therapy \[[@ref33]\]. Trastuzumab, an inhibitor of *ERBB2*, has been used for systemic therapy in patients with advanced SDC with promising responses \[[@ref34]--[@ref37]\]. SDC is also associated with androgen-receptor positivity in 67%--96% of cases, and, recently, a prospective phase II study showed that combined androgen blockade had equivalent efficacy and less toxicity for patients with androgen-receptor positive recurrent/metastatic or unresectable locally advanced SGC compared with conventional chemotherapy, which warrants further investigation \[[@ref38]--[@ref40]\]. Even PD-L1 expression and its correlation with survival and other promising therapeutic targets are under investigation in SDC and other histologies of SGC \[[@ref41], [@ref42]\].

In our cohort, patients with SDC relapsed more, and high histologic grade was a negative prognostic indicator for overall survival, which is in accordance with previous data. Only few patients were treated with palliative chemotherapy, due to its modesty activity. Data on the role of systemic therapy in the management of SGC is limited, and chemotherapy is generally reserved for advanced disease, when it is not suitable to surgery and/or radiation \[[@ref13]\]. A systematic review of published data in the management of metastatic or locally recurrent adenoid cystic SGC demonstrated major objective responses in nine of 36 patients treated with CAP regimen (response rate 25%, 95% CI 11%--39%), but even in just four trials analysed, doses were different \[[@ref43]\]. We had an adenoid cystic SGC patient with almost 3 years of progression-free survival after first line chemotherapy with CAP regimen for lung recurrence (500/50/50 mg/m^2^, q21d, six cycles). Despite the lack of robust data to support carboplatin-based regimens, we used it in combination with paclitaxel \[[@ref44], [@ref45]\], with manageable toxicity profile and progression-free survival between two and 28 months. A small number of patients were submitted to *ERBB2* and androgen receptor status determination and none was treated with targeted therapy, despite the positivity rate of 33.3% and 54.5%, respectively.

The present study was limited by its retrospective design and a small number of patients included, with multiple histologies. Prospective clinical trials, including those analysing the efficacy of adjuvant therapy and targeted therapy, are warranted. Priority should be given, also, to the molecular understanding of these tumours. Nevertheless, due to SGC rarity, such studies will be difficult to perform, and we must start to analyse what we have now, to aggregate multicenter data and set priorities for the future.

Conclusions
===========

In our cohort, the most frequent histological type was SDC, which is estimated to represent only 9% of salivary tumours \[[@ref2]\]. Patients with SDC relapsed more, and high histologic grade was a negative prognostic indicator for overall survival. Only a few patients were treated with palliative chemotherapy, mainly with CAP regimen or combined carboplatin and paclitaxel.
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###### Demographics, clinical-pathological and treatment features.

  -----------------------------------------------------------------------------------------------------------------------
  Characteristics                                                                                           *n*   \%
  -------------------------------------------------------------- ------------------------------------------ ----- -------
  Sex                                                            Male\                                      48\   51.6\
                                                                 Female                                     45    48.4

  Age                                                            Median, years\                             64\   
                                                                 Interquartile Range, years                 23    

  Eastern Cooperative Oncology Group (ECOG) performance status   0\                                         21\   22.6\
                                                                 1\                                         5\    5.4\
                                                                 2\                                         1\    1.1\
                                                                 3\                                         1\    1.1\
                                                                 Missing                                    65    65.9

  Primary site                                                   Parotid gland\                             71\   76.3\
                                                                 Submandibular gland\                       21\   22.6\
                                                                 Sublingual gland                           1     1.1

  Histological type                                              Salivary duct carcinoma\                   20\   21.5\
                                                                 Adenoid cystic carcinoma\                  15\   16.1\
                                                                 Mucoepidermoid carcinoma\                  13\   14.0\
                                                                 Myoepithelial carcinoma\                   11\   11.8\
                                                                 Acinic cell carcinoma\                     9\    9.7\
                                                                 Carcinoma ex pleomorphic adenoma\          6\    6.5\
                                                                 Squamous cell carcinoma\                   6\    6.5\
                                                                 Oncocytic carcinoma\                       3\    3.2\
                                                                 Basal cell adenocarcinoma\                 3\    3.2\
                                                                 Adenocarcinoma, not otherwise specified\   3\    3.2\
                                                                 Small cell carcinoma\                      1\    1.1\
                                                                 Carcinosarcoma\                            1\    1.1\
                                                                 Low-grade cribriform cystadenocarcinoma\   1\    1.1\
                                                                 Solitary fibrous tumour                    1     1.1

  Stage T                                                        pT1\                                       26\   28.0\
                                                                 pT2\                                       27\   29.0\
                                                                 pT3\                                       22\   23.7\
                                                                 pT4\                                       12\   12.9\
                                                                 Missing                                    6     6.5

  Stage N                                                        pN0\                                       41\   44.1\
                                                                 pN1\                                       6\    6.5\
                                                                 pN2\                                       8\    8.6\
                                                                 pN3\                                       3\    3.2\
                                                                 pNx\                                       29\   31.2\
                                                                 Missing                                    6     6.5

  Stage M                                                        cM0\                                       82\   88.2\
                                                                 cM1\                                       8\    8.6\
                                                                 Missing                                    3     3.2

  Grade                                                          High\                                      23\   24.7\
                                                                 Intermediate\                              8\    8.6\
                                                                 Low\                                       17\   18.3\
                                                                 Missing                                    45    48.4

  Lymphovascular invasion                                        Yes\                                       21\   22.6\
                                                                 No\                                        48\   51.6\
                                                                 Missing                                    24    25.8

  Perineural invasion                                            Yes\                                       35\   37.6\
                                                                 No\                                        37\   39.8\
                                                                 Missing                                    21    22.6

  Carcinoma ex pleomorphic                                       Yes\                                       6\    6.5\
                                                                 No\                                        55\   59.1\
                                                                 Missing                                    32    34.4

  Extracapsular spread                                           Yes\                                       9\    9.7\
                                                                 No\                                        52\   55.9\
                                                                 Missing                                    32    34.4

  Facial nerve sacrifice                                         Yes\                                       17\   23.9\
                                                                 No\                                        45\   63.4\
                                                                 Missing                                    9     12.7

  *ERBB2* status                                                 Positive\                                  2\    2.2\
                                                                 Negative\                                  4\    4.3\
                                                                 Missing                                    87    93.5

  Androgen receptor status                                       Positive\                                  6\    6.5\
                                                                 Negative\                                  5\    5.4\
                                                                 Missing                                    82    88.2

  Local treatment                                                Surgery\                                   93\   100\
                                                                 Adjuvant radiotherapy\                     66\   71\
                                                                 Adjuvant chemoradiotherapy                 3     3.2

  Systemic treatment                                             Adjuvant chemotherapy\                     1\    1.1\
                                                                 Palliative chemotherapy                    9     9.7
  -----------------------------------------------------------------------------------------------------------------------

###### Univariate analysis of DFS and OS.

  --------------------------------------------------------------------------------------------
  Characteristic             DFS, years                 OS, years                    
  -------------------------- -------------------------- ----------- --------- ------ ---------
  Sex                        Male\                      3.0\        0.015     4.9\   0.047
                             Female                     NR                    NR     

  Age, years                 \<65\                      NR\         0.225     NR\    0.098
                             ≥65                        7.9                   4.3    

  Primary site               Parotid gland\             NR\         0.990     7.7\   0.510
                             Other                      NR                    NR     

  Histological type          Salivary duct carcinoma\   1.8\        \<0.001   3.1\   \<0.001
                             Other                      NR                    NR     

  Stage T                    pT1-2\                     NR\         0.023     NR\    0.001
                             pT3-4                      3.2                   3.4    

  Stage N                    pN0-1\                     NR\         \<0.001   7.8\   \<0.001
                             pN2-3                      2.8                   2.5    

  Grade                      High\                      1.8\        \<0.001   3.1\   \<0.001
                             Intermediate/Low           NR                    NR     

  Lymphovascular invasion    Yes\                       2.0\        0.001     3.2\   0.001
                             No                         NR                    NR     

  Perineural invasion        Yes\                       3.6\        0.028     4.0\   0.004
                             No                         NR                    NR     

  Carcinoma ex pleomorphic   Yes\                       NR\         0.283     4.9\   0.322
                             No                         NR                    7.7    

  Extracapsular spread       Yes\                       3.0\        0.094     2.5\   \<0.001
                             No                         NR                    NR     

  Facial nerve sacrifice     Yes\                       3.2\        0.613     4.9\   0.509
                             No                         NR                    NR     

  *ERBB2* status             Positive\                  1.8\        0.782     5.1\   0.317
                             Negative                   1.3                   3.2    

  Androgen receptor status   Positive\                  1.8\        0.682     3.2\   0.578
                             Negative                   NR                    5.3    

  NR---not reached.                                                                  
  --------------------------------------------------------------------------------------------

###### Multivariable analysis of DFS and OS.

  ------------------------------------------------------------------------------------------------------
  Characteristics           DFS                        OS                                        
  ------------------------- -------------------------- -------------- ----------- -------------- -------
  Sex                       Male\                      36.4\          0.057       3.2\           0.28
                            Female                     (0.9-1473.6)               (0.4-26.4)     

  Histological type         Salivary duct carcinoma\   43.5\          0.043       6.1\           0.310
                            Other                      (1.1-1686.1)               (0.2-201.1)    

  Stage T                   pT1-2\                     0.72\          0.800       0.05\          0.132
                            pT3-4                      (0.06-8.7)                 (0.0-2.4)      

  Stage N                   pN0-1\                     0.45\          0.624       9.6\           0.379
                            pN2-3                      (0.02-11.1)                (0.1-1492.9)   

  Grade                     High\                      0.0\           0.936       0.02\          0.044
                            Intermediate/Low           (0.0-6965.0)               (0.001-0.9)    

  Lymphovascular invasion   Yes\                       0.13\          0.129       0.35\          0.488
                            No                         (0.01-1.8)                 (0.02-6.9)     

  Perineural invasion       Yes\                       7.4\           0.167       0.57\          0.623
                            No                         (0.4-127.9)                (0.06-5.3)     

  Extracapsular spread      Yes\                       NA             0.02\       0.075          
                            No                                        (0.0-1.5)                  

  NA---not applicable.                                                                           
  ------------------------------------------------------------------------------------------------------
